The nation of Zimbabwe has declined a significant American health deal valued at $367m (272 million pounds) spanning five years because of the United States' insistence on sensitive information.
This move was revealed following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson later stated that the United States was requesting biological samples for scientific study and commercial purposes but was unwilling to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued talks to secure a agreement acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This development comes after a comparable case in neighbouring Kenya, where a high court halted a related health funding agreement after concerns were raised about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen nations in Africa have so far agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the end products would be available to our citizens if a future disease outbreak emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending structures previously established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation could be arranged in a manner that respects the independence and dignity of each country."
Health Experts Reaction
A leading public health body stated it acknowledged the government's concerns, but recommended that negotiations need to persist considering much of the nation's Aids initiatives depended on external financing.
"In cases where technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it commented.
The situation highlights the complex debate between accepting vital international aid and safeguarding local interests in an ever more data-driven world.